Novel use of a short-acting intravenous beta blocker in combination with inotropic therapy as a bridge to chronic oral beta blockade in patients with advanced heart failure

Paul J. Hauptman, Daniel Woods, Marc R. Pritzker

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Abstract

The role for beta blockers in advanced heart failure (New York Heart Association class IV) remains undefined because of concerns about tolerability and uncertainty about efficacy. We report the use of a short-acting intravenous beta blocker in combination with inotropic therapy as a means to bridge five patients with advanced heart failure to chronic oral beta blockade; two of these patients had been chronically managed with intravenous inotrope. At 4 months' follow-up, all patients remained on beta-blocker therapy and none was hospitalized for heart failure or had received intravenous diuretics. Given the early separation of survival curves in the randomized clinical trials of beta blockers in heart failure, it is possible that these patients will accrue a survival benefit. We conclude that some patients with advanced heart failure can be offered oral betablocker therapy by bridging with a combination of intravenous inotrope and short-acting intravenous beta blocker.

Original languageEnglish (US)
Pages (from-to)247-249
Number of pages3
JournalClinical Cardiology
Volume25
Issue number5
DOIs
StatePublished - Jan 1 2002

Keywords

  • Beta blocker
  • Heart failure
  • Inotropic agent

Fingerprint Dive into the research topics of 'Novel use of a short-acting intravenous beta blocker in combination with inotropic therapy as a bridge to chronic oral beta blockade in patients with advanced heart failure'. Together they form a unique fingerprint.

Cite this